The New 340B ADR Final Rule Process: Overview and Implications for the Future (On-Demand Webinar)

Date: 11/07/24

Closed captions are available.

Overview: This webinar examines the final rule implementing an Alternative Dispute Resolution (ADR) process for disputes between 340B Drug Pricing Program covered entities and the drug manufacturers required to sell outpatient drugs to those entities at discounted prices. Speakers examine the ADR process and its application to claims alleging drug manufacturers are overcharging 340B covered entities and restrictions on the use of contract pharmacies by covered entities, as well as manufacturers’ claims of duplicate discounts or diversion. The session also discusses how the final rule may shape future relationships between covered entities, drug manufacturers, and HRSA.

Learning Objectives: 

• Explain the 340B framework and the relationships between 340B covered entities and drug manufacturers.
• Describe application of the final rule to disputes between 340B covered entities and drug manufacturers.
  
• Discuss the path forward and how the final rule may shape future relationships between covered entities, drug manufacturers, and HRSA.
  

Speaker Information:

Douglas A. Grimm, Partner, Arentfox Schiff LLP

Greg Doggett, Vice President, Legal and Policy Counsel, 340B Health

Laurence J. Freedman, Member, Mintz